Dr. Takebe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
31 Center Drive Bldg 31 Suite 3A44
Bethesda, MD 20892Phone+1 240-781-3398Fax+1 240-541-4515
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1994 - 1999
California Pacific Medical CenterResidency, Internal Medicine, 1991 - 1994
OtherClass of 1988
Certifications & Licensure
CA State Medical License 1992 - Present
MD State Medical License 1999 - 2025
OK State Medical License 2024 - 2025
NY State Medical License 1994 - 1999- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Testing the Safety of CB-5339 in Patients With Cancer Start of enrollment: 2020 Jun 18
- Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel Start of enrollment: 2020 Aug 24
- A Phase 1 Trial of the p97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas
Publications & Presentations
PubMed
- 749 citationsTargeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathwaysNaoko Takebe, Pamela Jo Harris, Ronald Q. Warren, S. Percy Ivy
Nature Reviews. Clinical Oncology. 2011-02-01 - 1 citationsThe Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs.Ukhyun Jo, Yasuhiro Arakawa, Astrid Zimmermann, Daiki Taniyama, Makito Mizunuma
Molecular Cancer Therapeutics. 2024-07-02 - 84 citationsQuantitative O6-Methylguanine DNA Methyltransferase Methylation Analysis in Curatively Resected Non-Small Cell Lung Cancer: Associations with Clinical OutcomeJan Brabender, Henning Usadel, Ralf Metzger, Paul M. Schneider, JiMin Park
Clinical Cancer Research. 2003-01-01
Lectures
- Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD1775.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Phase I trial of z-endoxifen with estrogen receptor imaging in adults with advanced hormone receptorâ€positive solid tumors including desmoid and gynecologic tumors.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
